

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-16 (canceled).

17. (not entered) A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTACTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAACTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT
9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. (not entered) The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. (new) A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA;
and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. (new) The method of claim 19, wherein the biological fluid is blood.

21. (new) A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA;
and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. (new) The method of claim 21, wherein the biological fluid is blood.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com